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Introduction: The contribution of the contact system to arterial thrombosis is unclear, results of clinical studies
are conﬂicting. Particularly, little is known about the involvement of the contact system in the progression of
arterial thrombosis. Therefore, we investigated the activation of the contact system during an acute myocardial
infarction (AMI) and 3 and 6 months following the acute event.
Methods: Plasma of patients with a ﬁrst AMI was collected on admission and 3 and 6 months after the AMI. The
levels of complexes of activated factor XI (FXIa), FXIIa and kallikrein with C1 esterase inhibitor (C1INH) and the
levels of complexes of FXIa withα1-antitrypsin (AT) were measured in these plasmas. Recurrent cardiovascular
events were recorded during a one year period after the AMI.
Results: We observed that the levels of FXIa-C1INH were elevated during the acute phase compared to the
steady-phase 3 and 6 months after the AMI. The levels of FXIa-AT, FXIIa-C1INH and kallikrein-C1INH did not
change over time. The levels of FXIa-C1INH, FXIa-AT, FXIIa-C1INH and kallikrein-C1INH were not predictive
for a recurrent event.
Conclusion:Weobserved that during an AMI, the activation of FXI was increased. The levels of FXIIa-C1INHwere
not elevated, suggesting that activation of FXI during the acute phase did not result from contact activation. The
levels of the enzyme inhibitor complexes were not predictive for a recurrent event one year after the ﬁrst AMI.© 2013 Elsevier Ltd. All rights reserved.Introduction
Acute myocardial infarction (AMI) is a major cause of morbidity
and mortality worldwide. It is the result of partial or complete occlu-
sion of the coronary arteries due to coronary thrombus formation,
impairing myocardial blood supply. A hypercoagulable state, character-
ized by activation of the coagulation system, is detectable in patients
with AMI [1–3]. Furthermore, within atherosclerotic lesions, coagulation
factors, including contact factor components, are abundantly present [4].
This way, hypercoagulability in blood and in atherosclerotic lesionsA.U, arbitrary units; C1INH,
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rights reserved.may have impact on the course of atherosclerosis as well as the risk
of atherothrombotic complications.
The role of the contact activation system of coagulation in the de-
velopment and progression of coronary artery disease (CAD) is still
unclear. In animal studies, deﬁciency in coagulation factor XI (FXI) or
FXII is associatedwith a decreased risk for arterial thrombosis, however,
the results from clinical studies are not straightforward. Several studies
found that high levels of FXI or activated FXI (FXIa) are associated with
an increased risk of CAD [2,5,6], however, in studies focussing only on
women this association is less clear [7–9]. Furthermore, FXI deﬁciency
does not protect against AMI [10]. The association between FXII and
CAD is complex, with a different association depending on whether zy-
mogen or enzyme levels were measured. Low levels of FXII were found
to be a risk factor for AMI, coronary heart disease (CHD) and all-cause
mortality [5,11,12], high levels of FXIIa and low levels of FXIIa in com-
plex with its main natural inhibitor C1-esterase inhibitor (FXIIa-C1INH)
were associated with an increased risk of CHD [13–18]. However, other
studies that measured FXII, FXIIa or FXIIa-C1INH did not conﬁrm an
association with CHD [6,8,12,19,20]. In all these studies the levels of
FXI or FXII were measured at one single time point. We set up a study
to determine the activation of the contact system during the acute
Table 1
Baseline characteristics of the study population.
Total group Male Female
N (%) 89 (100%) 66 (74%) 23 (26%)
Age, years (range) 61 (34 – 88) 60 (39 – 83) 66 (34 – 88)
Hypertension, n (%) 23 (25.8%) 18 (27.3%) 5 (21.7%)
Smoking, n (%) 5 (5.6%) 3 (4.5%) 2 (8.7%)
Type 2 diabetes, n (%) 47 (52.8%) 33 (50.0%) 14 (60.9%)
Hypercholesterolemia, n (%) 18 (20.2%) 14 (21.2%) 4 (17.4%)
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these data to determine whether contact activation could be used as a
marker for the occurrence of a recurrent thrombotic event.
Materials and Methods
Study Design
The study design has been described previously [21]. Consecutive
patients with a ﬁrst AMI were included. Patients were included if they
met the following inclusion criteria: chest pain lasting longer than
30 min but not exceeding 24 h, ST-segment elevation > 1 mm on
electrocardiography and biochemical evidence of myocardial necrosis.
Exclusion criteria were a history of AMI or stroke and present use of
oral anticoagulants. Blood samples were drawn on admission and be-
fore administration of low-molecular-weight-heparin (LMWH) or any
other intervention and repeated after 3 months and 6 months. To rule
out the use of LMWH before blood sampling, anti-Xa levels were deter-
mined in all baseline samples. Only samples with undetectable anti-Xa
(≤0.05 U ml-1) were considered to be free of LMWH and only these
samples were included in the analysis.
The clinical outcome was recorded 3 months, 6 months and
12 months after inclusion. The combined endpoint comprised cardiovas-
cular death, recurrent MI, a second coronary intervention [percutaneous
coronary intervention (PCI) or coronary artery bypass grafting (CABG)]
and ischemic stroke. The study protocol was approved by the Medical
Ethics Review Committee of the Maastricht University Medical Center,
the Netherlands. All patients gave written informed consent. Venous
blood was collected in 10 mM EDTA containing 100 μg ml-1 soybean
trypsin inhibitor (STI) and 20 mM benzamidine for the measurement of
enzyme inhibitory complexes and in 3.2% (w/v) citrated tubes for other
measurements.
Assays
The levels of FXIa, FXIIa and kallikrein in complex with C1-esterase
inhibitor (C1INH) and FXIa in complexwithα1-antitrypsin (FXIa-C1INH,
FXIIa-C1INH, kallikrein-C1INH and FXIa-AT) were measured in plasma
with enzyme-linked immunosorbent assays (ELISAs), as described pre-
viously [18]. The detection limits were 0.03 arbitrary units (A.U.) for all
assays and values below the detection limit were set at 0.03 A.U. The
inter- and intra-assay coefﬁcient variations (CVs) of these assays have
been published [18].
The levels of FXIc and FXIIc were determined by one-stage aPTT-
based clotting assays, performed on a SysmexCA-7000Automated Coag-
ulation Analyzerwith reagents obtained fromDade Behring (Liederbach,
Germany) and calibrated to WHO standards. D-dimer measurements
in platelet-poor plasma were performed using the Ddimer Plus test
(Dade Behring Inc., Liederbach, Germany) according to the manufac-
turer’s instructions. Prothrombin fragment 1.2 (F1.2) was quantiﬁed
by ELISA according to the manufacturer’s instructions (Dade Behring
Inc.). Anti-Xa activity was determined using the Coamatic Heparin test
(Instrumentation Laboratory, Breda, the Netherlands).
Statistical Analysis
The data are expressed as median [interquartile range (IQR)] or as
mean (standard deviation (SD)). Differences between two groups
were analysed using the Mann–Whitney U test (levels of inhibitory
complexes, D-dimer and F1.2) or the Student’s t-test (levels of FXIc
and FXIIc), depending on distribution characteristics. Correlations
between the enzyme inhibitory complexes were determined using
Spearman’s rho correlation. The difference in the levels of the inhibi-
tory complexes between the different time points was determined by
the Friedman test, followed by the Dunn’s multiple comparison test.
The association between dichotomized levels of enzyme inhibitorycomplexes and outcome was assessed using Pearson chi-square test,
and expressed as corresponding odds ratios (ORs) and 95% conﬁdence
intervals (CIs). Results were viewed to be statistically signiﬁcantly dif-
ferent at p b 0.05. Statistical analyses were performed using IBM SPSS
Statistics 20 for Windows (Armonk, New York: IBM Corp.) and Prism
for Windows 5.00 (GraphPad Software Inc., San Diego, CA, USA).
Results
Of the 135 patients included in this clinical study, plasma samples
of 89 patients on admission were available for the measurement of
enzyme inhibitory complexes. In total, 16 patientswere excluded because
anti-Xa levels were > 0.05 Uml-1. Of 30 patients, the availability of plas-
ma was not sufﬁcient to perform analyses. The baseline characteristics of
these 89 patients are represented in Table 1. Of them 14 had a recurrent
cardiovascular event during the follow-up period of 1 year. The levels of
the enzyme inhibitory complexes on admission did not differ between
patients stratiﬁed for gender, smoking or the presence of hypertension,
diabetesmellitus or hypercholesterolemia and did not correlate with age.
Enzyme-inhibitory Complexes
From 70 patients, complete sets of plasma samples from the three
time points (on admission and at 3 months and 6 months after the
acute event) were available to measure the levels of the enzyme in-
hibitory complexes. Fig. 1 shows the levels of the enzyme inhibitory
complexes on admission and during the follow-up period. For most
patients, the levels of FXIa-C1INH were highest on admission and de-
clined during follow-up. There was a statistically signiﬁcant reduction
in FXIa-C1INH complex levels with 55.7% of the patients at 3 months
and 70% at 6 months showing a decline in this inhibitor complex
compared with levels on admission. The median level of FXIa-C1INH
declined by 7.2% [IQR: -19.9% - 25.9%] and 9.5% [IQR: -7.1% - 22.1%]
at 3 and 6 months, respectively. The levels of FXIa-AT, FXIIa-C1INH
and kallikrein-C1INH did not change signiﬁcantly over time.
Because of the wide distribution of the data we were interested
to determine the correlation for each enzyme-inhibitor complex, com-
paringdifferent timepoints. The levels of FXIa-C1INHon admission, cor-
related well with the levels at 3 months and at 6 months (Spearman’s
rho: 0.84 and 0.88 p b 0.001, respectively). The same was true for the
levels of FXIIa-C1INH (Spearman’s rho: 0.77 and 0.87 p b 0.001, respec-
tively) and FXIa-AT (Spearman’s rho: 0.76 and 0.77 p b 0.001, respec-
tively). Since only few samples had levels above the detection limit for
kallikrein-C1INH, we did not perform correlation analyses for this en-
zyme inhibitor complex. These high correlations indicate that patients
with relatively high or low level of an enzyme inhibitor complex at
one time point, will most likely remain relatively high or low at a later
time point.
Recurrent Events
Table 2 shows the differences in the levels of FXIc, FXIIc, D-dimer,
F1.2 and the enzyme inhibitory complexes on admission between pa-
tients that developed a recurrent event during follow-up and those
that did not. The levels of D-dimer and F1.2 were higher in the
Fig. 1. Levels of FXIa-C1INH (A), FXIa-AT (B), FXIIa-C1INH (C) and kallikrein-C1INH (D) of patients after a ﬁrst myocardial infarction. Levels of activated factor XI (FXIa), FXIIa and
kallikrein in complex with C1 esterase inhibitor (C1INH) and FXIa in complex with α1-antitrypsin (AT) were measured in patients with a ﬁrst acute myocardial infarction (AMI) on
admission (0 days) and 3 and 6 months after the AMI. Difference between the groups were determined by Friedman test for repeated measures. The gray line depicts the median value. *
P b 0.05. IQR: interquartile range.
140 J. Konings et al. / Thrombosis Research 132 (2013) 138–142patients that had a recurrent event during follow-up. The levels of the
other factors did not differ between the groups. Fig. 2 shows the dis-
tribution of FXIa-C1INH, FXIa-AT, FXIIa-C1INH and kallikrein-C1INH
among patients that had an event during follow-up and those that did
not. There was no signiﬁcant difference between the groups. To get
more insight into the predictive value of FXIa-C1INH, FXIa-AT and
FXIIa-C1INH, we also determined the odds ratios (OR) for a recurrent
event after dichotomizing the data to low levels (b median of the total
group) versus high levels (≥ median of the total group) of FXIa-C1INH
and FXIa-AT and low levels (below detection limit) and high levels
(above detection limit) for FXIIa-C1INH. The OR for high compared to
low levels of these enzyme inhibitory complexes were: 0.49 (95% CI:
0.15 – 1.6), 1.85 (95% CI: 0.57 – 6.04) and 0.99 (95% CI: 0.30 – 3.25) for
FXIa-C1INH, FXIa-AT and FXIIa-C1INH, respectively. Only one sample
had kallikrein-C1INH levels above the detection limit, therefore no OR
was determined.Table 2
Levels of FXIc, FXIIc, D-dimer, F1.2, FXIa-C1INH, FXIa-AT, FXIIa-C1INH and kallikrein-C1INH
during a follow-up period of 1 year.
All patients Recurrent even
FXIc (U dl-1) 119 (17) 117 (25)
FXIIc (U dl-1) 101 (21) 101 (15)
D-dimer (ng ml-1) 370 [260 – 740] 625 [382 – 132
F1.2 (nmol ml-1) 227 [174 – 319] 314 [207 – 666
FXIa-C1INH (A.U.) 0.22 [0.17 – 0.35] 0.20 [0.17 – 0.3
FXIa-AT (A.U.) 0.26 [0.23 – 0.31] 0.29 [0.25 – 0.3
FXIIa-C1INH (A.U.) 0.03 [0.03 – 0.05] 0.03 [0.03 – 0.0
Kallikrein-C1INH (A.U.) 0.03 [0.03 – 0.03] 0.03 [0.03 – 0.0
Levels of FXIc and FXIIc are expressed as mean (standard deviation). The other levels ar
inhibitor.Discussion
Although experimental studies show an involvement of the con-
tact system of coagulation in arterial thrombosis, atherosclerosis
and ischemic stroke, very little is known about the role of the contact
activation system in humans. One problem in the human studies is in-
consistency in data in relation to outcomes, due to heterogeneity in
patient populations as well as in assays that were performed. Another
issue is that in previous clinical studies in all cases contact activation
indices were determined at one point in time, potentially missing pat-
terns of changes in time that may distinguish acute phase responses
from constitutive activity levels.
In this study, we investigated the activation of the contact system
of coagulation during the acute phase, and 3 and 6 months after an
AMI. Furthermore, we explored whether activation of the contact sys-
tem during the acute phase could be used to predict clinical outcomeof acute myocardial infarction patients stratiﬁed for the occurence of a recurrent event
t No recurrent event p-value (recurrent compared
to no recurrent event)
119 (15) 0.68
101 (22) 0.99
5] 360 [260 – 680] 0.04
] 213 [170 – 299] 0.03
0] 0.22 [0.17 – 0.41] 0.47
5] 0.26 [0.23 – 0.30] 0.17
6] 0.03 [0.03 – 0.05] 0.92
3] 0.03 [0.03 – 0.03] 0.67
e expressed as median [interquartile range]. A.U: arbitrary units, C1INH: C1-esterase
Fig. 2. Levels of FXIa-C1INH (A), FXIa-AT (B), FXIIa-C1INH (C) and kallikrein-C1INH (D) on admission in patients who suffered from a ﬁrst myocardial infarction. The levels of ac-
tivated factor XI (FXIa), FXIIa and kallikrein in complex with C1 esterase inhibitor (C1INH) and FXIa in complex with α1-antitrypsin (AT) are subdivided into patients with a recur-
rent cardiovascular event within the ﬁrst year after the AMI and those that did not have a recurrent event. The gray line depicts the median value.
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the levels of the activated enzymes in complex with their natural
inhibitors: FXIa, FXIIa and kallikrein in complex with C1INH and
FXIa in complex with AT. We ensured that samples did not contain any
anticoagulant by careful selection at inclusion as well as by screening
samples by anti-Xa activity for spurious LMWH presence (data not
shown) [21].
We found that the levels of FXIa-C1INH were elevated during the
acute event in patientswith a ﬁrst AMI compared to the steady state sit-
uation at 3 and 6 months after the AMI. We did not observe this effect
for FXIa-AT. Upon activation, C1INH is the main inhibitor of FXIa, but,
the half-life of the FXIa-AT complex in vivo is longer than the half-life
of FXIa-C1INH: 349 min and 104 min respectively [22]. Because of
this, FXIa-AT reﬂects chronic activation of FXI whereas FXIa-C1INH
better reﬂects the acute phase response [22]. This is illustrated in a pre-
vious study, where in 20 patients with either an AMI (blood sampling 7
to 10 days after the event) or unstable angina, the levels of FXIa-AT
were signiﬁcantly elevated but the levels of FXIa-C1INHwere compara-
ble to controls [22]. In contrast, Minnema and colleagues showed that
patients with an AMI had higher levels of FXIa-C1INH during the
acute attack compared to patients with stable angina pectoris. In these
patients, the levels of FXIa-ATwere not elevated during the acute attack
[2]. In contrast to the present study, they did not obtain follow up blood
samples, such that the comparison could only be made between those
with AMI and patients with either unstable or stable angina [2].
The levels of FXIIa-C1INHwere not elevated during the acute attack,
suggesting that in these patients FXI activation was probably caused by
an increase in thrombin generation rather than by FXII activation.
Indeed, as reported previously, thrombin generation capacity was in-
creased during AMI. Themeasurement of the endogenous thrombin po-
tential (ETP) in these patients, showed that the ETP-valueswere highest
during the acute attack and were diminished 3 and 6 months after the
event [21].
We observed that higher levels of D-dimer and F1.2 on admission
were associated with a recurrent cardiovascular event in the year
following the ﬁrst AMI in this study. This is in agreement with earlier
ﬁndings. The level of the activation peptide of prothrombin, F1.2, was
found to be elevated in patients with ACS and was associated withcardiac mortality and long-term outcome in patients with ACS [23–25].
Elevated levels of D-dimer are observed in patients with ACS [25] and
are a predictor for coronary heart disease [26]. Furthermore, elevated
levels of D-dimer are predictive of a recurrent coronary events in
post infarction patients and in patients with ischemic-type chest pain
[27,28]. In our study the levels of the inhibitory complexes on admission
were not predictive for the occurrence of a recurrent event in the year
after the ﬁrst AMI. High levels of FXIa-C1INH, FXIa-AT, FXIIa-C1INH
and kallikrein-C1INHwere not a risk factor for the occurrence of a re-
current cardiovascular event during the follow-up period. Possibly,
the study was underpowered to demonstrate the predictive value
for the enzyme-inhibitory complexes, however, the OR’s were in no
way indicative of any risk association. Similarly, in a larger study in
patients with chest pain, the levels of FXIa-C1INH, FXIa-AT, FXIIa-
C1INH and kallikrein-C1INH were also not predictive for clinical out-
comes 2 years after admission. This was the case both for patients
with TnT-levels ≤ 0.05 ng ml-1 and TnT-levels > 0.05 ng ml-1 on ad-
mission [20].
We observed a high correlation between the levels of the enzyme
inhibitory complexes on admission and those during follow-up. This
indicates that in patients with relatively high levels of enzyme inhibitory
complexes, these levels stay relatively high. However, they did not pre-
dict a recurrent cardiovascular event in the year after a ﬁrst AMI. This
highlights the fact that in spite of a marked interindividual variation in
constitutive levels of contact activation, the link between individual levels
of these products and arterial vascular disease remains to be explored.
In conclusion, we observed that during an AMI the levels of FXIa-
C1INH were elevated compared to the steady state 3 and 6 months
after the AMI. In the absence of evidence of acute FXII activation,
the temporary increase may primarily result from thrombin generation
and feedback FXI activation. Themain contribution of FXII in this regard
may be in starting and strengthening (arterial) clot formation [29]. The
clinical signiﬁcance of contact activation in the context of coronary ar-
tery disease remains to be demonstrated.
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